

July 27, 1997

File 351:DERWENT WPI 1963-1997/UD=9729;UP=9726;UM=9723

(c)1997 Derwent Info Ltd

\*File 351: Excluded from Web promotion. OnTap file 280 is reloaded.  
See HELP FAQ 351 for reload info. British Apps faster - HELP NEWS 351.

Set	Items	Description
---	-----	-----
?ss ax=90-248420		or ax=91-073315 or ax=94-083973
S1	1	AX=90-248420
S2	1	AX=91-073315
S3	1	AX=94-083973
S4	3	AX=90-248420 OR AX=91-073315 OR AX=94-083973

?t s4/3,ab/1-3

4/3,AB/1

DIALOG(R)File 351:DERWENT WPI

(c)1997 Derwent Info Ltd. All rts. reserv.

009804118

WPI Accession No: 94-083973 /199411

XRAM Accession No: C94-038573

Venom cream - comprises refined snake venom enzyme, transfer factor,  
borneol and pre-prepd. mixed matrix NoAbstract

Patent Assignee: UNIV CHINA MEDICAL (UYCH-N)

Inventor: HAO W; SUN J; ZHU L

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
CN 1072344	A	19930526	CN 92109960	A	19920929	A61K-037/48	199411 B

Priority Applications (No Kind Date): CN 92109960 A 19920929

Basic Derwent Week: 199411

4/3,AB/2

DIALOG(R)File 351:DERWENT WPI

(c)1997 Derwent Info Ltd. All rts. reserv.

008569280

WPI Accession No: 91-073315 /199110

Related WPI Accession No: 93-188534

XRAM Accession No: C91-031014

Pharma-cosmetic compsn. comprising snake-venom from Crotalus atrox -  
useful for tropical treatment e.g. arthritis, rheumatism, muscular  
ache(s), etc.

Patent Assignee: VARANUSZ GM (VARA-N)

Inventor: BODROGI L; HETENYL L; POLUS P

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
WO 9101740	A	19910221					199110 B
AU 8941815	A	19910311					199123

Priority Applications (No Kind Date): WO 89HU39 A 19890805

Filing Details:

Patent	Kind	Filing Notes	Application	Patent
--------	------	--------------	-------------	--------

WO 9101740 A

Designated States (National): AU DK FI JP NO US

Designated States (Regional): AT BE CH DE FR GB IT LU NL SE

Abstract (Basic): WO 9101740 A

Prodn. of pharmacocosmetics comprising snake-venom comprises incorporating  
(pref. lyophilised) toxin Grotali atrocis in amt. of 0.0002-0.1% (of total)  
into an ointment, aq. suspension, emulsion or gel compsn., etc., with usual  
additives and/or auxiliaries.

USE - For topical treatment of rheumatism, arthritis, arthrosis,  
ischial, lumbago, muscular aches following sport, etc..

Dwg.0/0

Basic Derwent Week: 199110

July 27, 1997

4/3,AB/3

DIALOG(R)File 351:DERWENT WPI

(c)1997 Derwent Info Ltd. All rts. reserv.

008361419

WPI Accession No: 90-248420 /199033

XRAM Accession No: C90-107263

**Snake venom peptide prodn. - by solid-phase synthesis**

Patent Assignee: GARSKY V M (GARS-I); MERCK & CO INC (MERI )

Inventor: GARSKY V M

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
EP 382538	A	19900816	EP 90301353	A	19900208		199033 B
CA 2009613	A	19900809					199043
JP 2275899	A	19901109	JP 9027311	A	19900208		199051

Priority Applications (No Kind Date): US 89308846 A 19890209

Filing Details:

Patent	Kind	Filing Notes	Application	Patent
EP 382538	A			

Designated States (Regional): CH DE FR GB IT LI NL

Abstract (Basic): EP 382538 A

Peptides of formula H-(Ch)-Cys-R-R-R-Arg (I) (is effected) attaching the C-terminal amino acid to a solid crosslinked polystyrene Pam resin, and sequentially coupling each successive amino acid; (b) removing the N-terminal Boc gp.; (c) cleaning the peptide from the resin with HF and oxidising the peptide with a mixt. of p-thiocresol and p-cresol; (d) filtering the residue from step (c) and transferring it to a large vol. of 0.4% aq. MOAc; and stirring the soln. and adjusting the pH to 8: (where Ch and Cx = at least one amino acid; each R is an amino acid (same or different)).

USE/ADVANTAGE - The process is used for prodn. of snake-venom peptides, esp. echistatin, which are used for inhibiting fibrinogen binding to human platelets and for inhibiting fibrinogen-induced platelet aggregation. Gives high yields of (I) with correct folding and with minimal intermolecular crosslinking. (8pp Dwg.No.0/0)

Basic Derwent Week: 199033

?pause.

>>> PAUSE started.

?

RECEIVED

11-03-1997

REINHOLD COHN AND PARTNER:

## The preparation of snake toxin ointment

This patent is about the method of preparation of an external use drug, snake toxin ointment, which can cure some skin diseases, gynaecology diseases, and wounds.

Its composition, based on weight, is as follow: snake toxin enzyme 0.25-5%, Franfer factor 0.1-10%, Bingpian, a Chinese medicine, 0.1-2%, and the others are the mixture of some organic chemicals which act as the base materials of this drug.

This drug can function as antibiotics, but no toxicity and side effect.

The appearance of this drug is the outcome of effort to look for more potent drug under the challenge of growing resistance of bacterial to antibiotics, which has the same activity as antibiotic, which is more convenient for use, and which has shorter course of treatment and less by-effect.

Why does it has antibiotic activity? Based on some experiments, it's assumed that a metal complex has been formed in the drug from some inorganic components in the Chinese medicine, metal elements and some organic molecules, and this complex has significant pharmaceutical activity and that some trace elements in it have nutritional role.

As proved by clinical use, this drug has such function as, resisting coagulation, dissolving thrombus, improving capillary circulation, and dilating blood vessel. In addition, it's observed in the lab that this drug has some neural growth nutritional substance.

The snake toxin enzyme is available in the market.

Franfer factor is a kind of peptide of small molecular weight, generated by leucocyte. It is a newly developed immune regulator and promoter, which can improve immunity. Since this factor has no antigenicity, there is no rejection for injection and no need of considering matching as done in the injection of active immune cells. This factor has little side effect and it has wide effect, even for herpes zoster.

Bingpian, a Chinese medicine, has such role as, relieving pain, inhibiting the growth of bacterial and counteracting inflammation, etc. It will be easily absorbed by mucosa subcutaneous tissue.

### Preparation method 1.2.3.4

#### Analysis

##### 1.Trace element analysis

##### 2.Toxicology experiment. LD50=19.3±1.77u/kg

Through histo-enzymechemistry micrograph and electric micrograph, it's proved that this drug has no harm on liver.

### 3. Pharmacology experiment

The snake toxin ointment can cure thrombo-vascular-inflammation, diabetes mellitus gangrene, and has effect on some skin diseases ,functioning like antibiotics. In addition, it can improve capillary circulation and the nutrition state of pathogenic cells.

Through clinical use, it's proved that this drug can cure children eczema 100% and some other skin diseases 81.2%.